Skip to main content

Table 2 Pharmacodynamic parameters based on anti-Xa measurements * after subcutaneous administration in 20 healthy volunteers

From: Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

  Average MW Mna Dose t½ Renal clearance Total clearanceb
(Da) (Da) (IU) (h) (% of dose) (mL/min)
Enoxaparin 4,400 3,100 2,000 3.95 ± 0.65 6.4 ± 6.5 16.67 ± 5.50
4,000 4.37 ± 0.47 8.7 ± 3.4 13.83 ± 3.17
Nadroparin 4,400 3,700 3,075 3.74 ± 0.68 3.9 ± 1.8 21.50 ± 7.00
Dalteparin 5,700 4,750 2,500 2.81 ± 0.84 3.4 ± 1.5 33.33 ± 11.83
  1. aNumber average MW; bCl/F.
  2. *Clinical data were extracted from Collignon et al [36] and compiled specifically for this review (MW data from Schroeder et al [31]).